- With new data, Regenxbio to seek FDA approval of Duchenne gene therapyThough two serious side effects muddied the results, CEO Curran Simpson expressed optimism about a clearance and claimed FDA leadership will have a “mandate on rare disease flexibility.”BioPharma Dive · 2mo ago↗ source
- Case Introduction and ctDNA as Emerging Risk Factoronclive · 2mo ago↗ source
- ASCO 2026: All Eyes Are on Daraxonrasib and a Wave of Novel Targeted Therapies in GI MalignanciesAhead of the 2026 ASCO Annual Meeting, experts in GI malignancies share the most anticipated research being presented during the meeting.onclive · 2mo ago↗ source